Perseus Proteomics (TYO:4882) and UBE have entered a collaborative research agreement focused on antibody-drug conjugates (ADC), which are used to kill cancer cells, according to its filing on Monday.

The partnership will enhance the development of PPMX-T004, an ADC, and explore additional ADCs using external drug discovery sources.

Their combined technologies will optimize antibody and drug/linker combinations for effective treatments.

Price (JPY): $610.00, Change: $+2.0, Percent Change: +0.33%